Group A: Newly Diagnosed

Inclusion Criteria:

- Patients > 18 years of age.

- Confirmed diagnosis of HL or NHL (any histology).

- Any Ann Arbor stage.

- Pre-treatment staging including CT of head and neck, chest, abdomen and pelvis, where
there is a minimum one equivocal finding on the scan, affecting the assignment of
stage or IPI factor (i.e. stage III/IV vs. stage I/II, or a question of extranodal
involvement by disease).

Group B: Response Assessment

Inclusion Criteria:

- Patients > 18 years of age.

- Confirmed diagnosis of HL or NHL (any histology).

- Any Ann Arbor stage.

- Pre-treatment staging including CT neck, chest, abdomen and pelvis. If alternate
assessment of the neck done by clinical palpitation, ultrasound, or MRI is negative,
CT neck is not mandatory.

- Post-treatment staging including CT of head and neck, chest, abdomen and pelvis, at 1
- 6 weeks post-therapy.

- Treated with anthracycline-based chemotherapy, with or without radiation therapy
(based on the stage of the disease). For Stage III/IV patients, PET will be done
following completion of primary chemotherapy. For stage I/II patients, PET will be
done after combined modality therapy, or after chemotherapy alone if this was the
primary intention of therapy.

- Patients with residual mass on CT following primary chemotherapy with either
"unconfirmed" CR (>75% decrease in size) or PR (³50% decrease in size), based on
International workshop criteria.

Exclusion Criteria: Response Assessment

- None Curative treatment Intent

- After initial therapy the response status is: complete response, stable disease, or
progressive disease